A Prospective, Randomized, Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1)
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs CMX 2043 (Primary)
- Indications Myocardial reperfusion injury
- Focus Adverse reactions; Biomarker
- Acronyms SUPPORT-1
- 10 Jun 2017 Biomarkers information updated
- 21 Jun 2011 Planned number of patients changed from 120 to 220.
- 21 Jun 2011 Status changed from recruiting to completed.